de JongVRazA.Sub-therapeutic doses in the treatment of depression. The implications of starting low and going slow. J Mind-Body Regul. 2011;1(2):73–84.
2.
KirschI.The emperor's new drug: Exploding the antidepressant myth. London (GB): Bodley Head; 2009.
3.
SachseCBrockmöllerJBauerSCytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284–295.
4.
BijlMJVisserLEHofmanAInfluence of the CYP2D6 4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65:558–564.
5.
McCormackJPAllanGMViraniAS. Is bigger better? An argument for very low starting doses. CMAJ. 2011;183:65–69.
6.
CohenJS. How drug-company policies cause problems for 50 to 75 percent of patients taking Prozac. In: CohenJS. Overdose: The case against the drug companies. New York (NY): Tarcher-Putnum; 2001. p 36–49.
